NMN vs NR: Which NAD+ Precursor Is Better? (2026 Data)

Key Takeaways

NMN and NR (nicotinamide riboside) both raise NAD+ through convergent biochemical pathways, so the NMN vs NR debate centers on which precursor is more efficient. The first head-to-head human trial, published in Nature Metabolism, compared three NAD+ boosters including NMN and NR and measured their differential impact on circulatory NAD+ levels and microbial metabolism (Christen et al., 2026). What is NMN’s theoretical advantage? It sits one enzymatic step closer to NAD+ than NR, requiring only NMNAT conversion rather than the two-step NR → NMN → NAD+ pathway, though whether this translates to clinically meaningful differences in humans remains under investigation.

This has been the most debated question in the longevity supplement space for years. Until January 2026, the debate was theoretical, no human trial had ever compared them in the same study. That changed. Here's what the data actually shows.

What did the 2026 NMN-vs-NR trial find?

The 2026 Christen trial was the first to directly compare NMN, NR, and niacin. All three raised blood NAD+, with the precursors performing similarly on that marker. NMN carries more total human RCTs and a higher tested dose, but no precursor clearly beat the others on hard functional outcomes.

According to Christen et al. (2026, Nature Metabolism), 65 healthy adults were randomized into four groups receiving 1, 000 mg/day of NMN, NR, nicotinamide (NAM), or placebo for 14 days. This was the first randomized controlled trial to directly compare NAD+ precursors in humans under identical conditions.

The results were clear: NMN and NR both approximately doubled circulating NAD+ concentrations. There was no statistically significant difference between them. Nicotinamide raised NAD+ acutely (at the 4-hour mark) but did not sustain elevated levels over 14 days.

Both NMN and NR also modulated the gut microbiome to increase short-chain fatty acid (SCFA) concentrations, metabolites linked to stronger gut barrier function and reduced systemic inflammation. Nicotinamide did not produce this effect. The researchers found evidence that gut bacteria convert both NMN and NR into nicotinic acid, suggesting the microbiome plays a larger role in NAD+ metabolism than previously recognized.

Harvard geneticist David Sinclair, PhD, whose lab has published extensively on NMN and NAD+ biology, has argued that NMN supplementation can meaningfully raise blood NAD+ levels over a couple of weeks, though reported magnitudes vary across studies, a direction broadly consistent with the Christen et al. findings for both precursors.

How NMN and NR Reach NAD+: Two Different Paths

The NMN-versus-NR debate is a one-enzyme question: NR needs two conversion steps to reach NAD+ while NMN needs one, yet NMN's larger size may force partial conversion back to NR for cellular entry, blurring the advantage. NR holds the longer safety record; NMN holds the landmark metabolic trial (PMID: 33888596). Both demonstrably raise blood NAD+.

NR pathway: NR enters cells directly through equilibrative nucleoside transporters (ENTs). Once inside, the enzyme NR kinase converts it to NMN, which then becomes NAD+. This is a well-characterized route.

NMN pathway: NMN is too large to pass through most cell membranes directly because of its phosphate group. According to a 2025 comprehensive review by Yang et al. (Food Frontiers), the primary route is: NMN is dephosphorylated outside the cell by CD73 → converted to NR → enters the cell as NR → reconverted to NMN → becomes NAD+.

There is one exception: researchers identified a transporter called Slc12a8 in the mouse small intestine that can transport NMN directly into cells. However, this transporter has not been confirmed in other human tissues, and its functional relevance in humans remains uncertain.

The practical implication: NMN's "one step closer to NAD+" marketing claim is technically accurate in terms of the biosynthetic pathway, but the cell entry route means NMN likely converts to NR before entering most cells anyway. The 2026 head-to-head data confirms what this biochemistry predicts, no meaningful difference in the end result.

Does NR have more evidence than NMN?

Not more, but different. NR has been studied longer and has solid NAD+-raising data, while NMN now has more total human RCTs and higher tested doses. NR converts to NMN before becoming NAD+, making NMN one step closer. Neither has proven decisively superior on functional outcomes.

NR entered human trials earlier and has accumulated a significantly larger evidence base. The patented form (Niagen/NIAGEN) has been used in over 40 published human clinical studies covering heart health, metabolic function, neurological conditions, and exercise performance.

NMN's clinical evidence base is smaller but growing fast. Since 2022, the pace of published NMN human trials has accelerated dramatically, now totaling 12+ studies covering NAD+ elevation, physical performance, sleep quality, insulin sensitivity, and telomere length.

A 2025 review by Yang et al. in Food Frontiers provided the first comprehensive side-by-side analysis of NMN and NR preclinical and clinical data. Their conclusion: both compounds reliably raise NAD+ levels, but the evidence base for NR is more mature, while NMN's is catching up.

An April 2026 systematic review (preprint, bioRxiv) attempted the first indirect meta-analytic comparison of NMN vs. NR on metabolic endpoints. The authors concluded that the trial populations, doses, and durations were too heterogeneous to draw reliable indirect comparisons, reinforcing why the Christen et al. head-to-head trial matters so much.

What are the key differences between NMN and NR?

1. Regulatory Status

NR (as Niagen) has held FDA GRAS status since 2015 and was reviewed under the FDA's New Dietary Ingredient (NDI) notification program in 2015 and 2018. NMN faced regulatory uncertainty when the FDA briefly questioned its supplement status in 2022. That was resolved in September 2025 when the FDA confirmed NMN qualifies as a dietary supplement.

Both are now legal to sell as supplements in the US. But NR's longer regulatory track record means it has been commercially available, and commercially tested, for a longer period.

2. CD38 Inhibition

This is the least-discussed but potentially most important difference. CD38 is an enzyme whose activity increases with age and inflammation, and it consumes NAD+. According to published research, NR appears to inhibit CD38 activity, helping preserve existing NAD+ pools in addition to boosting production.

NMN has not been shown to inhibit CD38. This means NR may offer a dual mechanism: it both increases NAD+ supply and reduces NAD+ destruction. Whether this translates into meaningful clinical differences is unknown, no human trial has measured CD38 inhibition as a primary endpoint for either compound.

3. Gut Microbiome Effects

According to the 2026 Christen et al. trial, both NMN and NR increased gut short-chain fatty acid concentrations. Nicotinamide did not. The researchers found that gut bacteria convert both NMN and NR into nicotinic acid, a potent NAD+ booster, suggesting the microbiome mediates part of their effect.

This is a new discovery. No prior study had examined gut microbiome effects of NAD+ precursors. It means part of the benefit may come from feeding your gut bacteria, not just from direct NAD+ conversion.

4. Price

NMN has historically been more expensive than NR on a per-milligram basis, though prices have dropped significantly since 2024 as more suppliers entered the market and manufacturing scaled up. NR's patented form (Niagen) carries a premium for the established brand, but generic NR is also available at lower prices. At equivalent doses, the cost difference is narrowing.

5. Dose-Response Data

NMN has stronger dose-response data from the Yi et al. (2023) multicenter trial, which tested 300, 600, and 900 mg/day and found that 600 mg/day hit the optimal threshold for both NAD+ elevation and functional improvement. NR's dose-response curve is less precisely characterized in published trials, though a 2018 study showed 500 mg twice daily (1, 000 mg total) raised NAD+ by approximately 60%.

Who Might Prefer NMN

NMN may be a better fit if you want the most recent research backing (the 2026 head-to-head data, the Yi et al. dose-response data), if you value having precise dose-response information to guide your protocol, or if you're already following researchers like David Sinclair who have used NMN in their own protocols.

NMN also has broader functional outcome data, published trials measuring walking speed, grip strength, sleep quality, and insulin sensitivity, not just NAD+ levels. If you're looking for evidence that goes beyond "it raises NAD+" and into "it changes how you function, " NMN's recent trial portfolio is compelling. For a full breakdown, see our NMN Benefits guide and NMN Dosage guide.

Who Might Prefer NR

NR may suit people who want the longer-established precursor with more years of safety data and wide commercial availability, or who prefer a compound that's been through more regulatory review. The trade-off is that NR takes an extra conversion step to NMN, and recent trials show no clear functional edge over NMN.

NR may be a better fit if you prioritize a longer track record of published safety data (40+ studies), a more established regulatory history (FDA GRAS since 2015), or if the potential CD38 inhibition mechanism is important to you.

NR has also been tested in more clinical populations, including studies in individuals with cardiovascular conditions and neurological concerns, giving it a broader safety dataset across diverse health profiles. If you're over 60 or managing a chronic condition, the deeper NR safety literature may provide more reassurance.

What About Nicotinamide (NAM)?

The 2026 Christen et al. trial included a nicotinamide arm as a control. The result was unambiguous: nicotinamide raised NAD+ acutely at 4 hours but failed to sustain elevated levels over 14 days. It also did not increase gut SCFAs.

Nicotinamide is the cheapest NAD+ precursor and the most widely available (it's standard vitamin B3). But if sustained NAD+ elevation is your goal, the clinical data now clearly shows it falls short compared to both NMN and NR. You get what you pay for.

What this means: They're Closer Than the Marketing Suggests

The 2026 head-to-head trial settled the central question: NMN and NR produce equivalent NAD+ elevation in humans. The supplement industry has spent years positioning them as rivals, but the biochemistry, and now the clinical data, shows they're more like two routes to the same destination.

The real differences are at the margins: NR's larger evidence base and CD38 inhibition vs. NMN's stronger dose-response data and broader functional outcome trials. For most people, either one is a reasonable choice. The more important decisions are dose (250–600 mg/day based on published data), consistency (daily for at least 4–12 weeks), and product quality (third-party tested for identity and potency).

Don't spend hours agonizing over NMN vs. NR. Pick one, take it consistently at a clinically studied dose, and evaluate how you feel after 8–12 weeks. That's what the science supports.

If you choose NMN, see our NMN supplement, 500 mg per capsule, third-party tested for identity and potency. For dosing guidance, see our NMN Dosage guide.

Related Research

• PubMed: 36476934
• PubMed: 27304511
• PubMed: 35821806
• PubMed: 34326206
• PubMed: 17086191
• PubMed: 21261636
• PubMed: 35927255

Related Reading

• NMN And Resveratrol
• NMN Before And After
• NMN vs Nad
• What Is NMN? NAD+ Science Explained

Which raises NAD+ more efficiently?

Both precursors work; the question is path efficiency. NR converts via NR → NMN → NAD+; NMN skips a step but may require transporter-mediated or conversion-dependent entry in some tissues. The deciding evidence: NMN anchored the Science 2021 insulin-sensitivity trial (PMID: 33888596), while NR carries more cumulative human safety data.

NR (nicotinamide riboside) enters cells via equilibrative nucleoside transporters and is phosphorylated intracellularly by NRK1/NRK2 to become NMN, which is then adenylylated to NAD+. The pathway: NR → NMN → NAD+. NMN can enter cells through the recently identified Slc12a8 transporter (Grozio 2019) and is converted to NAD+ in one enzymatic step: NMN → NAD+. In theory, NMN requires one less conversion step inside the cell, which some researchers argue makes it more efficient.

In practice, both compounds raise blood NAD+ levels comparably at their respective studied doses. The Martens 2018 NR trial (1, 000 mg/day) and the Yi 2023 NMN trial (600 mg/day) both documented significant NAD+ elevation. The question is whether the downstream effects, the endpoints that actually matter for healthspan, differ between the two precursors. No head-to-head trial has compared NMN and NR in the same cohort for clinical outcomes, so any claim that one is definitively "better" than the other is extrapolating beyond the evidence.

The practical considerations that may influence your choice: NMN has more recent and more numerous human RCTs (12+ versus approximately 8 for NR). NR has been on the market longer and has more long-term safety surveillance data. NMN is generally more expensive per dose. NR is available from established supplement brands with longer track records. Neither compound has demonstrated lifespan extension in humans. See NMN benefits for the current clinical evidence on each endpoint.

The bioavailability debate: does NMN or NR raise NAD+ more effectively?

The central question in the NMN versus NR comparison is which precursor raises intracellular NAD+ more efficiently. Both compounds are converted to NAD+ through well-characterized enzymatic pathways, but they take different routes. NR enters cells via equilibrative nucleoside transporters and is phosphorylated to NMN by NRK1/2 enzymes, then converted to NAD+ by NMNAT enzymes. NMN was previously thought to require extracellular conversion to NR before entering cells, but the Slc12a8 transporter discovered by Grozio et al. (2019) demonstrated direct NMN uptake in the small intestine, bypassing the NR intermediate step.

In human trials, both compounds raise blood NAD+ levels. The Yi 2023 NMN study and the Martens 2018 NR study both documented meaningful NAD+ elevation, though head-to-head comparison is complicated by different doses, populations, and measurement methods. No trial has directly compared NMN and NR in the same cohort using the same endpoint.

Which is the best NAD+ supplement?

By volume of human clinical trial data: NMN has more published RCTs (12+ versus approximately 6 for NR as of 2026). By regulatory status: NR has been available longer as a commercial supplement and has more established manufacturing supply chains. By cost: NR is generally less expensive per serving. By dose convenience: NR requires lower milligram doses (300 to 1, 000 mg) compared to NMN (250 to 1, 250 mg). Neither compound has demonstrated clear superiority in functional outcomes (as opposed to biomarker changes) in published trials. The practical choice often comes down to price, availability, and individual tolerance rather than a definitive evidence advantage. See NMN benefits for what the precursor actually delivers.

Why are NMN and NR regulated differently?

An important factor in the NMN versus NR decision is regulatory status, which differs between countries and has shifted over time. In the United States: NR (as Niagen, manufactured by ChromaDex) received New Dietary Ingredient (NDI) notification acceptance from the FDA in 2015, establishing a clear regulatory pathway for supplement sales.

NMN's regulatory status has been more contested, the FDA briefly considered classifying NMN as an investigational drug (which would remove it from the supplement market), but as of 2026 it remains available as a dietary supplement. The regulatory uncertainty has affected NMN pricing and brand stability.

In the European Union: both NMN and NR are classified as novel foods and require pre-market authorization. Availability varies by member state. In Asia: both compounds are widely available in Japan, South Korea, and China without significant regulatory barriers.

For consumers: the regulatory picture does not determine which compound is more effective, it determines which is more reliably available and quality-controlled. NR's longer regulatory history means more established manufacturing standards and third-party testing infrastructure. NMN's newer market entry means more variability in product quality, making third-party testing verification (COA with ≥99% purity by HPLC) especially important when purchasing NMN.

Should you choose NMN or NR?

If cost is the primary concern: NR is typically 20 to 40% cheaper per daily dose than NMN, with comparable (though not identical) NAD+-raising efficacy in the limited head-to-head data available.

If evidence depth matters most: NMN has more published human RCTs (12+ versus approximately 6 for NR), providing a broader base of safety and efficacy data.

If convenience matters: NR requires lower milligram doses (300 to 600 mg) than NMN (250 to 1, 000 mg), meaning fewer or smaller capsules per day.

If you want the newer research: NMN is the more actively researched compound as of 2026, with a faster-growing publication rate. Most new NAD+ precursor trials are using NMN rather than NR.

Either compound raises blood NAD+. Neither compound has proven lifespan extension in humans. Both are safe at studied doses. The practical difference for most consumers is smaller than the marketing suggests. See NMN benefits and NMN dosage.

Can you get NAD+ precursors from food?

Before spending $50 to $100/month on NMN or NR supplements, consider that your body synthesizes NAD+ from three dietary precursors: tryptophan (via the de novo synthesis pathway), niacin/niacinamide (via the Preiss-Handler and salvage pathways), and NMN/NR (via the salvage pathway). Optimizing dietary intake of the first two is free and may provide meaningful NAD+ support without supplementation.

Tryptophan-rich foods (turkey, chicken, eggs, dairy, tofu): the de novo pathway converts tryptophan to NAD+ through a multi-step enzymatic process. This pathway is less efficient than the salvage pathway but contributes meaningfully to total NAD+ production, especially when dietary tryptophan is adequate.

Niacin-rich foods (liver, tuna, chicken breast, peanuts, mushrooms): niacin (vitamin B3) is a direct NAD+ precursor. At RDA levels (14 to 18 mg/day), niacin prevents pellagra but may not optimize NAD+ production. Higher dietary niacin intake (50 to 100 mg/day from food) supports stronger NAD+ synthesis without supplementation.

The supplement decision then becomes: is the additional NAD+ elevation from NMN or NR (40 to 100% above what diet alone achieves) worth $50 to $100/month? For someone with excellent dietary habits including adequate tryptophan and niacin, the incremental benefit of supplementation may be smaller than for someone with a poor diet. Optimize diet first, then evaluate whether supplemental precursors provide additional benefit worth the cost.

For the individual NMN evidence: benefits, dosage, side effects, timing, before and after expectations, NMN plus resveratrol.

NMN vs NAD+ vs NR, what's the difference?

The alphabet soup of NAD+ precursors confuses even experienced supplement users, partly because the terms are used interchangeably in marketing and partly because the biochemistry involves multiple intermediate steps that get collapsed into oversimplified claims.

Why is NAD+ the goal, not the supplement itself?

Nicotinamide adenine dinucleotide (NAD+) is the coenzyme that both NMN and NR are trying to replenish. You cannot effectively supplement NAD+ directly by mouth because it is a large molecule that degrades in the digestive tract before reaching systemic circulation. Intravenous NAD+ infusions bypass this barrier, which is why IV clinics charge hundreds of dollars per session, but the evidence for IV NAD+ superiority over oral precursors is thin, based primarily on pharmacokinetic studies showing acute blood-level spikes without corresponding evidence of superior long-term health outcomes. The oral supplementation strategy is to take a smaller precursor molecule (NMN or NR) that survives digestion and then gets converted to NAD+ inside your cells through established biosynthetic pathways.

Why does the conversion pathway matter?

NR (nicotinamide riboside) enters cells and is phosphorylated by NR kinases (NRK1 and NRK2) into NMN, which is then adenylylated into NAD+. NMN supplementation skips the NRK step entirely, entering the pathway one step closer to NAD+. For years, it was debated whether NMN could even enter cells directly or had to be dephosphorylated back to NR first, the discovery of the Slc12a8 transporter in 2019 (Grozio et al., Nature Metabolism) demonstrated that NMN does have a direct cellular uptake pathway, at least in the small intestine. However, the relative contribution of direct NMN transport versus dephosphorylation-to-NR-then-rephosphorylation remains actively researched, and the clinical significance of this mechanistic distinction has not been resolved in human trials.

Why Some People Stop Taking NMN

Search queries about discontinuing NMN reveal a pattern worth addressing honestly. The most common reasons people stop fall into three categories. First, cost: quality NMN at 500–1000 mg daily runs $50–120 per month, and people who expected dramatic, obvious results within 30 days feel the investment is not justified by what they perceive. Second, biomarker disappointment: some users test their NAD+ levels before and after supplementation and find smaller increases than marketing materials implied, though this often reflects testing methodology limitations (whole blood NAD+ does not capture intracellular NAD+ in target tissues like muscle and brain). Third, side effects: a minority of users report insomnia, mild headaches, or GI discomfort during the first two weeks, particularly at doses above 500 mg. These typically resolve with dose reduction and gradual titration, but users who started at 1000 mg and experienced disrupted sleep may have abandoned the supplement before finding their tolerable dose.

The honest framework for evaluating NMN is not "did I feel 10 years younger in a month" but rather "over 6–12 months, do my energy levels, exercise recovery, and relevant biomarkers (fasting glucose, lipid panel, inflammatory markers) trend in the right direction?" The longevity thesis behind NAD+ replenishment operates on timescales of years, not weeks, and the evidence base, while promising, is still building toward the kind of long-term human outcome data that would justify certainty.

What is NMNH, the reduced form of NMN?

Reduced NMN (NMNh or NMNH) is a newer entrant in the precursor space. NMNH is the reduced form of NMN, carrying an extra hydrogen that positions it one enzymatic step closer to the reduced form of NAD (NADH). Early cell-culture studies suggest NMNH may be more efficient at raising NAD+ levels than NMN in certain tissues, and a 2022 mouse study found NMNH more potently increased hepatic NAD+ levels. However, no human pharmacokinetic or clinical trial data exists for NMNH as of mid-2025. The compound is also less stable than NMN, it oxidizes readily on exposure to air and moisture, raising questions about shelf-life and what fraction of the labeled dose remains bioactive by the time you take it. Until human data demonstrates a meaningful advantage, NMN remains the better-established choice with a larger safety and efficacy evidence base.

NMN or NR: which fits your situation?

If the mechanistic debate leaves you uncertain, a practical framework based on your priorities may help. Choose NR if: you value the largest evidence base and regulatory precedent (Tru Niagen's NR has FDA GRAS status, multiple published human trials, and the most safety data); you are cost-sensitive (NR is generally 20–40% cheaper per effective dose than NMN); or you are over 60 and want the best-characterized compound for this age group (most NR trials enrolled older adults specifically). Choose NMN if: you want the more direct NAD+ precursor pathway that skips the NR kinase step; you have tried NR without satisfactory results and want to test whether the different uptake mechanism produces better subjective outcomes for you; or you are interested in the emerging research on NMN's effects on physical performance; the 2022 Liao et al. study showed NMN improved aerobic capacity in recreational runners, an endpoint that has not been demonstrated with NR. For either choice, the effective dose range in human studies is 250–1000 mg daily, stability matters more than brand (look for third-party purity testing and proper storage recommendations), and the evaluation timeline is months, not days.

Why YourHealthier NMN

NMN lives and dies on purity, and that's the corner low-cost brands quietly cut. Our NMN provides 500mg of β-Nicotinamide Mononucleotide per capsule, third-party tested for identity and contaminants so what's on the label is what's in the bottle. We skip the longevity hype that dominates this space. Stated plainly: NMN reliably increases NAD+ in humans, but the anti-aging claims extrapolated from mouse studies haven't been confirmed in people. The part we can control is dosing accuracy and cleanliness, and given how costly NMN is to make, independent lab verification is really the only dependable way to separate real NMN from underdosed filler.

Who should be cautious with NMN

People with active or prior cancer. NMN raises NAD+ levels, which fuel cellular metabolism. Because cancer cells also rely on NAD+ for rapid growth, there is theoretical concern that boosting NAD+ could support tumor metabolism. The human evidence is unsettled, but anyone with a current or past cancer diagnosis should discuss NMN with their oncologist before using it.

Pregnant or breastfeeding women. There is no safety data for NMN during pregnancy or lactation. Avoid use during these periods.

People taking medications. NMN's interactions are not well characterized because it is a relatively new supplement. If you take any prescription medication, particularly for metabolic or cardiovascular conditions, consult your doctor first.

People expecting dramatic anti-aging effects. While NMN reliably raises NAD+ levels in humans, the longevity and anti-aging benefits demonstrated in mice have not yet been confirmed in large human trials. Set expectations accordingly and treat marketing claims with skepticism.

NMN appears well tolerated in short-term human studies, but its regulatory status has shifted in the United States, and long-term safety data is still developing. More detail: NMN benefits and the current evidence.

Frequently Asked Questions

Related Reading:

• NMN Benefits: What NAD+ Actually Does for Aging and Energy (2026)
• NMN Dosage: How Much Should You Take? (2026 Guide)
• Shilajit Benefits for Men: Testosterone, Energy & What Research Shows (2026)
• Creatine for Brain Health: Not Just for Athletes (2026)
• Ashwagandha Benefits: 7 Reasons It's the Most Popular Adaptogen
• Berberine Benefits: What It Does for Blood Sugar, Metabolism, and More
• Magnesium Glycinate Benefits: 7 Reasons It Beats Other Forms (2026)
• Lion's Mane Benefits: What This Mushroom Does for Your Brain and Body
• Best Supplements for Sleep: A Science-Based Ranking (2026)
• Is Berberine Safe Long-Term? 7 Risks Your Supplement Brand Won't Tell You
• How Long Does Creatine Take to Work? The Science-Backed Timeline
• Is Shilajit Safe? What the Research Actually Says (2026)
• Ashwagandha and Cortisol: The Science Behind Stress Relief

References

1. Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism. 2026;Jan 15. PubMed
2. Yang X, Lu A, Guan X, et al. An updated review on the mechanisms, pre-clinical and clinical comparisons of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Food Frontiers. 2025;6:630–643. DOI
3. Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults. GeroScience. 2023;45:29–43. PubMed
4. Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD levels and alters muscle function in healthy older men. NPJ Aging. 2022;8:5. PubMed
5. Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. 2016;7:12948. PubMed
6. Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism. 2019;1:47–57. PubMed
7. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372:1224–1229. PubMed
8. Song Q, Zhou X, Xu K, et al. The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update. Advances in Nutrition. 2023;14(6):1416–1435. PubMed
9. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism. 2018;27:513–528. PubMed

Disclosure: YourHealthier sells NMN supplements. We do not sell NR. This article compares both compounds based on published clinical evidence regardless of which one we carry. We cite the 2026 head-to-head trial, which found no significant difference between them, and present NR's advantages (larger evidence base, CD38 inhibition) alongside NMN's strengths (dose-response data, functional outcome trials). See our Editorial Policy for how we research and write.

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not intended as medical advice.

NMN vs NR: Head to Head

Metric	Value
NMN: NAD+ rise at 1g/14d (fold)	~2x
NR: NAD+ rise (fold)	~2x
NR human studies	40+, FDA GRAS
NMN dose (Yi 2023)	1,000 mg/day
Source: YourHealthier · 14-day trials; Yi 2023 multicenter

Chart: NMN vs NR: Head to Head. Data: NMN: NAD+ rise at 1g/14d (fold): ~2x; NR: NAD+ rise (fold): ~2x; NR human studies: 40+, FDA GRAS; NMN optimal dose (mg/day): Yi 2023. Source: 14-day trials; Yi 2023 multicenter.